PotomacRiver
Company
Our Story
Our Team
Our Location
Services
Policies & Procedures
Training
Communications
Auditing & Monitoring
Transparency & Aggregate Spend
Operational Excellence
Careers
What We Do
Why Potomac?
Current Openings
Interview Process
Frequently Asked Questions
Potomac Thinking
Year-in-Review
Currents
Presentations
Brochures
Conferences
Industry Resources
Contact
Potomac Thinking
Industry Resources
Laws and Regulations
Enforcement of the Drug Sample Distribution Requirements of the Prescription Drug Marketing Act (PDMA)
Federal Anti-Kickback Statute (AKS)
Federal Acquisition Regulation (FAR)
False Claims Act (FCA)
Federal Food, Drug and Cosmetic Act (FDCA)
FDA Amendments Act (FDAAA)
Foreign Corrupt Practices Act (FCPA)
Health Insurance Portability and Accountability Act (HIPAA)
Health Information Technology for Economic and Clinical Health Act (HITECH)
Patient Protection and Affordable Care Act (PPACA)
Prescription Drug Marketing Act (PDMA)
Sunshine Act
Sunshine Act Final Rule
UK Bribery Act
Codes
PhRMA Code on Interactions with Healthcare Professionals
Statement on Application of Section 2 of PhRMA Code during Emergency Periods
PhRMA Conduct of Clinical Trials
PhRMA Guiding Principles for DTC Advertisements
PhRMA Principles on Interactions with Patient Organizations
AdvaMed Code of Ethics
MDMA Code of Conduct on Interactions with Healthcare Professionals
EFPIA Code of Practice
Standards for Integrity and Independence in Accredited Continuing Education
Guidance
OIG General Compliance Program Guidance (November 2023)
OIG Special Fraud Alert: Speaker Programs (November 2020)
DOJ Guidance on Compliance (June 2020)
Internet/Social Media Platforms: Correcting Independent Third-Party Misinformation About Prescription Drugs and Medical Devices
OIG Compliance Program Guidance (January 2017)
OIG Advisory on Patient Travel & Lodging
DOJ/SEC FCPA Resource Guide
OIG PDMA Guidance
FDA PDMA COVID-19 Guidance
IFPMA Note for Guidance on Patient and Patient Organization Interactions
Year in Review